Navigation Links
Kitov Announces Completion of Manufacturing Pivotal Batches of KIT-302 Required for Registration in the U.S.
Date:5/27/2016

TEL-AVIV, Israel, May 27, 2016 /PRNewswire/ --

Kitov Pharmaceuticals (NASDAQ/TASE: KTOV), an innovative biopharmaceutical company focused on late-stage drug development, today announced the completion of manufacturing by Dexcel Pharma of pivotal batches required for registration of KIT-302 with the U.S. Food and Drug Administration (FDA). This follows Kitov's announcement in December 2015, that KIT-302's pivotal Phase III trial successfully met its primary efficacy endpoint.

"We are fortunate to have Dexcel as our manufacturing partner for KIT-302. Dexcel's state-of-the-art manufacturing capabilities enabled us to reach this CMC milestone in record time, and bring KIT-302 one step closer to the NDA submission and marketing approval," stated Kitov CEO Isaac Israel.

According to the Development Services Agreement executed between Kitov and Dexcel in April 2014 for KIT-302's chemical manufacturing and control (CMC), Dexcel oversees all CMC aspects of KIT-302 including analytical methods and validation, stability testing, and production of batches for pharmacokinetics and bioequivalence studies and scale-up required for New Drug Application (NDA) submission to the FDA, expected at the end of 2016.  

As part of the terms of this strategic agreement, Dexcel will pay Kitov $250,000 as a milestone payment for its right of first negotiation with regard to future marketing rights for KIT-302 and for an option to negotiate the future commercial manufacture of KIT-302. Kitov will make a milestone payment to Dexcel, which will consist of a $500,000 cash payment and 3,009,888 ordinary shares of Kitov (which are equivalent to 150,494 ADSs traded on the NASDAQ).

Dexcel is a global pharmaceutical company active in more than 30 countries including the U.S., the U.K., and Germany. Dexcel's portfolio includes some 55 drug products, both branded and generic, and Dexcel produces some 5 billion tablets and capsules in its Israeli manufacturing facilities, which meet cGMP standards with routine oversight by the FDA.

About Kitov Pharmaceuticals

Kitov Pharmaceuticals (NASDAQ/TASE: KTOV) is an innovative biopharmaceutical company focused on late-stage drug development. Leveraging deep regulatory and clinical-trial expertise, Kitov's veteran team of healthcare professionals maintains a proven track record in streamlined end-to-end drug development and approval. Kitov's pipeline currently features two combination drugs intended to treat osteoarthritis pain and hypertension simultaneously, including one that achieved the primary efficacy endpoint for its Phase III clinical trial. Lowering development risk and cost through fast-track regulatory approval of novel late-stage therapeutics, Kitov delivers rapid ROI and long-term potential to investors, while making a meaningful impact on people's lives. For more information, the content of which is not part of this press release, visit http://www.kitovpharma.com.

Forward-Looking Statements

This press release contains forward-looking statements about the Company's expectations, beliefs and intentions. Forward-looking statements can be identified by the use of forward-looking words such as "believe", "expect", "intend", "plan", "may", "should", "could", "might", "seek", "target", "will", "project", "forecast", "continue" or "anticipate" or their negatives or variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical matters. These forward-looking statements involve certain risks and uncertainties, including, among others, the risk that drug development involves a lengthy and expensive process with uncertain outcome; the Company's ability to successfully develop and commercialize its pharmaceutical product; the length, progress and results of any clinical trials; the introduction of competing products; the impact of any changes in regulation and legislation that could affect the pharmaceutical industry; the difficulty in receiving the regulatory approvals to commercialize the Company's products; the lack of sufficient funding to finance the clinical trials; the difficulty of predicting actions of the USA FDA; the regulatory environment and changes in the health policies and regimes in the countries in which we operate; or changes in the global pharmaceutical industry. . Any forward-looking statement in this press release speaks only as of the date of this press release. The Company undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws. More detailed information about the risks and uncertainties affecting the Company is contained under the heading "Risk Factors" in Kitov Pharmaceuticals Holdings Ltd.'s Registration Statement on Form F-1 filed with the SEC, which is available on the SEC's website, http://www.sec.gov .

Contact:

Simcha Rock
Chief Financial Officer
+972-2-6254124
Simcha@kitovpharma.com

Bob Yedid
Managing Director
LifeSci Advisors, LLC
+1-646-597-6989
bob@LifeSciAdvisors.com


'/>"/>
SOURCE Kitov Pharmaceuticals
Copyright©2016 PR Newswire.
All rights reserved


Related medicine technology :

1. Kitov Pharmaceuticals Appoints Dr. Gil Ben-Menachem as V.P. of Business Development
2. Kitov Pharmaceuticals Reports Additional Data from its Phase III Trial on the Beneficial Blood Pressure Effects of KIT-302
3. Kitov Pharmaceuticals Pivotal Phase III Trial Successfully Meets Primary Efficacy Endpoint
4. Kitov Pharmaceuticals to Announce Interim Results of the Pivotal Phase III Trial on December 15, 2015 at 7:00am ET
5. Kitov Pharmaceuticals Holdings Announces Closing of U.S. Initial Public Offering
6. Kitov Pharmaceuticals Holdings Announces Pricing of U.S. Initial Public Offering and NASDAQ Listing
7. Amarantus Announces Upcoming Investor Presentations
8. NxStage Announces Second Quarter 2016 Investor Conference Schedule
9. Celsion Announces Presentation of OVATION Study Clinical Trial Design at Upcoming ASCO 2016 Meeting
10. Elsevier Announces the Launch of Journal: Clinical Neurophysiology Practice
11. Gamida Cell Announces $4.4 Million Grant from the Israeli Government
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/14/2020)... ... , ... A new study from the National Alliance for Caregiving (NAC) and ... 9.5 million from 2015 to 2020 and now encompasses more than one in five ... worse health compared to five years ago. As the demand for caregiving rises with ...
(Date:5/14/2020)... ... 2020 , ... Clear Labs , providers of the only automated and ... funding led by Redmile Group, as well as existing investors including Wing VC, Menlo ... Labs has raised $62M. , In addition to supporting ongoing commercialization of the ...
(Date:5/14/2020)... ... May 13, 2020 , ... The DuPont Kingston Technology ... spread of COVID-19 in the local community. To date, more than 4,000 liters of ... and small businesses. An additional 2500 liters of hand sanitizer will be produced and ...
Breaking Medicine Technology:
(Date:5/21/2020)... CITY, Mich. (PRWEB) , ... May 21, 2020 , ... ... a hands-free door opener that allows users to open swing-style doors without using ... doors and allows people to pull the door open using their forearm, wrist or ...
(Date:5/21/2020)... (PRWEB) , ... May 21, 2020 , ... Friends of ... 35, has been endorsed by Planned Parenthood Southeast Advocates (PPSEA). PPSEA ... support family planning and the full range of reproductive health care. PPSEA educates and ...
(Date:5/21/2020)... ... 2020 , ... A new report from Kalorama Information, a market ... in the point of care test industry. Given the need to diagnose patients ... point-of-care more important than in the past, according to the market researcher. ...
(Date:5/16/2020)... (PRWEB) , ... May 15, 2020 , ... ... announced a new collaboration with the Open Source Medical Supplies (OSMS). The organization ... of their efforts to reduce the spread of COVID-19. , Created as a ...
(Date:5/15/2020)... ... 15, 2020 , ... On May 17, World NF Awareness Day, actors, musicians, ... Is, a benefit to support the Children’s Tumor Foundation and to Make NF Visible. ... on nerves throughout the body and affects all ethnicities, races, and genders equally. In ...
Breaking Medicine News(10 mins):